This note takes a quick look at the lessons learned and the existing landscape of MCM manufacturing in the context of the current pandemic response and suggests eight areas for action along with near-term recommendations to the global community to both prepare and respond to future pandemic risks. 

While oral antivirals are not a substitute for vaccination, they are key to preventing severe illness, saving lives, and preserving health systems. Vaccination rates continue to be low in low-income countries; only 14 percent of the population in low-income countries has received one dose of the vac...

The COVID-19 pandemic has transformed the global vaccine manufacturing landscape, with capacity more than doubling in the past 18 months. Before the pandemic, manufacturers produced an estimated total of five billion vaccine doses each year. In 2021, manufacturers produced 12 billion doses of C...

Providing patients with high-quality essential medicines requires a well-functioning procurement, distribution, and regulatory system. However, in many low- and lower-middle-income countries (LMICs), public sector supply chain performance is far from optimal, resulting in frequent stockouts at healt...

Over the past two decades, partnerships between bilateral and multilateral funders, philanthropy, national governments, and the private sector have substantially increased global access to effective malaria treatment. Nevertheless, further action on malaria case management is needed to meet global t...

Safe and efficacious vaccines are our best tools for defeating COVID-19, and an unprecedented research and development effort has led to 12 vaccines being approved for full, emergency, or limited use, globally. But to vaccinate the global population as quickly as possible requires additional product...